US4552982A - Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes - Google Patents

Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes Download PDF

Info

Publication number
US4552982A
US4552982A US06/519,166 US51916683A US4552982A US 4552982 A US4552982 A US 4552982A US 51916683 A US51916683 A US 51916683A US 4552982 A US4552982 A US 4552982A
Authority
US
United States
Prior art keywords
acid
carbamoyl
fluorene
hydrogen
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/519,166
Inventor
William B. Lacefield
William Pfeifer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US06/519,166 priority Critical patent/US4552982A/en
Priority to US06/685,924 priority patent/US4658061A/en
Priority to DK332585A priority patent/DK332585A/en
Priority to HU852828A priority patent/HU194537B/en
Priority to AT0221185A priority patent/AT383116B/en
Priority to CN198585106400A priority patent/CN85106400A/en
Assigned to ELI LILLY AND COMPANY, 307 EAST MCCARTY STREET, INDIANAPOLIS, INDIANA, 46285, A CORP OF INDIANA reassignment ELI LILLY AND COMPANY, 307 EAST MCCARTY STREET, INDIANAPOLIS, INDIANA, 46285, A CORP OF INDIANA ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: LACEFIELD, WILLIAM B., PFEIFER, WILLIAM
Application granted granted Critical
Publication of US4552982A publication Critical patent/US4552982A/en
Priority to JP60289085A priority patent/JPS61158944A/en
Priority to EP85309313A priority patent/EP0187509A3/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes

Definitions

  • 9-aminoalkylfluorenes recently has been disclosed as having valuable antiarrhythmic activity; see U.S. Pat. Nos. 4,197,313 and 4,277,495.
  • the 9-carbamoyl-9-aminoalkylfluorenes are among the most interesting compounds, and one compound within this group, namely 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene, is now known generically as indecainide.
  • Lavagnino et al. in U.S. Pat. No. 4,282,170, disclose a process for preparing 9-carbamoyl-9-(3-aminopropyl)fluorene, an intermediate in a synthesis of indecainide, which process comprises hydrogenation of 9-carbamoyl-9-(2-cyanoethyl)fluorene.
  • the hydrogenation reaction is said to be best carried out in an acidic medium, most preferably in glacial acetic acid, although organic solvents such as ethanol can be employed if desired.
  • An object of this invention is to provide an improvement in the process for hydrogenating 9-carbamoyl-9-(2-cyanoethyl)fluorene.
  • the improvement provided by this invention results in reduced amounts of the aforementioned fluorene dimer and trimer by-products being produced, and thereby permits formation of a purer pharmaceutical agent.
  • This invention concerns an improvement in a process for converting a cyanoethylfluorene to an aminopropylfluorene.
  • the invention more particularly provides, in the process for preparing a compound of the formula ##STR2## wherein R and R 1 independently are hydrogen, C 1 -C 4 alkyl, fluoro or chloro; and R 2 and R 3 independently are hydrogen or C 1 -C 6 alkyl, involving catalytically hydrogenating a compound of the formula ##STR3## the improvement comprising conducting the reaction in the presence of an acid medium stronger than glacial acetic acid.
  • the hydrogenation is carried out in the presence of trifluoroacetic acid. In another preferred embodiment the hydrogenation is carried out in the presence of a mineral acid such as hydrochloric acid.
  • the process provided by this invention is carried out by catalytically hydrogenating a 9-carbamoyl-9-(2-cyanoethyl)fluorene in an acid medium stronger than glacial acetic acid.
  • the hydrogenation of the cyano group of a cyanoethylfluorene can be accomplished employing any of the common hydrogenation catalysts, including platinum, palladium, nickel, rhodium and ruthenium.
  • the process generally will be carried out under a hydrogen pressure of about 1 to about 4 atmospheres, and typically at a temperature of about 20° to about 70° C.
  • the hydrogenation process of this invention can be carried out in essentially any organic solvent; all that is required is that about one molar equivalent or more of an acid stronger than glacial acetic acid be present in the reaction mixture.
  • Organic solvents that can be employed include alcohols, ethers, aromatics, amides, as well as organic or inorganic acids and mixtures of acids.
  • the process is conveniently carried out in an alcohol such as methanol or ethanol together with at least about one molar quantity, relative to the cyanoethylfluorene to be reduced, of a strong acid such as 12N hydrochloric acid or the like.
  • any acid that is stronger than acetic acid can be employed in the process of this invention.
  • Such acids include those having a pK a less than about 4.75, the pK a of glacial acetic acid at 25° C.
  • Exemplary of the strong acids that can be employed in the present process include benzosulfonic acid, any of the aminobenzosulfonic acids, ortho or meta-bromobenzoic acid, trichloroacetic acid, the chlorobenzoic acids, 2-chlorophenoxyacetic acid, 3-chlorophenoxyacetic acid, dimethylmalonic acid, dinicotonic acid, diphenylacetic acid, fluorobenzoic acid, formic acid, fluoroacetic acid, glycolic acid, hippuric acid, 2-hydroxybenzoic acid, 2-iodobenzoic acid, itacomic acid, lutidinic acid, maleic acid, malonic acid, mesaconic acid, methylmalonic acid, naphthalenesulfonic acid, ⁇
  • Inorganic acids can also be employed and exemplary of such acids are arsenic acid, chromic acid, hydrofluoric acid, hydrochloric acid, iodic acid, nitrous acid, periodic acid, phosphoric acid, pyrophosphoric acid, selenic acid, sulfuric acid, and related strong inorganic acids.
  • the hydrogenation process of this invention generally is substantially complete within about two to about twenty-four hours when carried out at about ambient temperature and under a hydrogen pressure of about 1 to about 4 atmospheres.
  • the 9-carbamoyl-9-(3-aminopropyl)fluorene that is produced by the process is readily isolated by established procedures if desired.
  • the reaction mixture can be filtered to remove the hydrogenation catalyst, and the reaction solvent can be removed from the filtrate, for instance by evaporation under reduced pressure.
  • the aminopropylfluorene product can be isolated and crystallized as an acid addition salt, or if desired the salt can be neutralized by reaction with a base such as sodium hydroxide or ammonium hydroxide to provide the desired primary amine.
  • the 9-carbamoyl-9-(3-aminopropyl)fluorene is not isolated, but rather is reacted further in situ to produce an N-alkyl derivative such as 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene.
  • alkylation is best accomplished by first neutralizing any excess acid, for instance by addition of a base such as sodium bicarbonate, and then simply adding an aldehyde or a ketone to the hydrogenation reaction mixture and subjecting the mixture to further hydrogenation.
  • the aldehyde or ketone reacts with the primary amino group of the 9-carbamoyl-9-(3-aminopropyl)fluorene to produce the corresponding Schiff base, which upon further hydrogenation is reduced to the desired N-alkyl derivative.
  • 9-carbamoyl-9-(2-cyanoethyl)fluorene can be hydrogenated according to this invention by reaction with hydrogen gas in the presence of a catalyst such as platinum oxide and a strong acid such as trichloroacetic acid to produce, substantially free of dimer or trimer by-products, 9-carbamoyl-9-(3-aminopropyl)fluorene.
  • the reaction mixture is neutralized by addition of a base, for example about one molar quantity or an excess of sodium hydroxide or the like.
  • a ketone such as acetone can be added to the neutralized reaction mixture and the mixture can be further hydrogenated to provide 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene.
  • the product thus produced is substantially free of undesired by-products and can be isolated and purified by routine procedures.
  • the reaction mixture was filtered and the filtrate was concentrated to dryness to provide 93.5 g of a white solid identified as primarily dimer and trimer product.
  • the solid was suspended in 500 ml of acetone and the mixture was stirred at 25° C. for one hour and then filtered to give 34 g of a white solid.
  • the filtrate was concentrated to give 50 g of a white solid.
  • the oil was added to 200 ml of ethyl acetate and 200 ml of ice water, and this mixture was diluted by addition of 400 ml of 6N hydrochloric acid.
  • the aqueous acid layer was separated, made alkaline by addition of 110 ml of 50% aqueous sodium hydroxide.
  • the aqueous alkaline solution was extracted several times with diethyl ether, and the ethereal extracts were combined, washed with water, dried and the solvent was removed by evaporation to give 13.4 g (76.1% yield) of product.
  • the product was shown by high performance liquid chromatography to be comprised of 83.4% 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene and 8.2% of dimer, N,N-bis-[3-(9-carbamoylfluoren-9-yl)propyl]amine, identical to that prepared and characterized in Example 1.
  • the reaction mixture was filtered and the filtrate was concentrated to 36.0 g of a viscous liquid.
  • the liquid was dissolved in 200 ml of water and the aqueous solution was washed with diethyl ether and then made alkaline by addition of 50% (w/v) aqueous sodium hydroxide.
  • the alkaline mixture was extracted several times with diethyl ether and the ethereal extracts were combined, washed with water and dried. Removal of the solvent by evaporation under reduced pressure afforded 9.6 g (82% yield) of a tan solid.
  • the product thus obtained was crystallized from 90 ml of hot (80° C.) isopropanol to give 4.8 g of 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene hydrochloride melting at 205°-207° C.
  • High performance liquid chromatography demonstrated the product to be at least 97.6% pure, with less than 1% of dimer being present.
  • the aqueous layer was made alkaline by addition of 50% (w/v) aqueous sodium hydroxide, and the aqueous alkaline solution was extracted several times with dichloromethane. The organic extracts were combined, washed with water, dried, and the solvent was removed by evaporation under reduced pressure to give 9.9 g (97% yield) of a tan solid identified by thin layer chromatography as 9-carbamoyl-9-(3-aminopropyl)fluorene.
  • the reaction mixture was filtered and the filtrate was concentrated to give 32.2 g of a viscous oil.
  • the oil was added to 200 ml of ice water and the aqueous mixture was made alkaline by addition of 50% (w/v) aqueous sodium hydroxide.
  • the aqueous alkaline mixture was extracted several times with diethyl ether.
  • the ethereal extracts were combined and extracted with 300 ml of 6N hydrochloric acid and 200 ml of water.
  • the aqueous acid extracts were combined, made alkaline by addition of fresh sodium hydroxide, and extracted with fresh diethyl ether.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

9-Carbamoyl-9-(2-cyanoethyl)fluorenes are converted to 9-carbamoyl-9-(3-aminopropyl)fluorenes by catalytic hydrogenation in the presence of a strong acid.

Description

BACKGROUND OF THE INVENTION
A group of 9-aminoalkylfluorenes recently has been disclosed as having valuable antiarrhythmic activity; see U.S. Pat. Nos. 4,197,313 and 4,277,495. The 9-carbamoyl-9-aminoalkylfluorenes are among the most interesting compounds, and one compound within this group, namely 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene, is now known generically as indecainide.
Lavagnino et al., in U.S. Pat. No. 4,282,170, disclose a process for preparing 9-carbamoyl-9-(3-aminopropyl)fluorene, an intermediate in a synthesis of indecainide, which process comprises hydrogenation of 9-carbamoyl-9-(2-cyanoethyl)fluorene. The hydrogenation reaction is said to be best carried out in an acidic medium, most preferably in glacial acetic acid, although organic solvents such as ethanol can be employed if desired.
We have now discovered that the hydrogenation process described in U.S. Pat. No. 4,282,170 leads to formation of observable quantities of fluorene dimer and trimer by-products, compounds of the formulas ##STR1## Removal of these by-products has proved extremely difficult, and in general they are carried through subsequent reactions and can be found in the final product.
An object of this invention is to provide an improvement in the process for hydrogenating 9-carbamoyl-9-(2-cyanoethyl)fluorene. The improvement provided by this invention results in reduced amounts of the aforementioned fluorene dimer and trimer by-products being produced, and thereby permits formation of a purer pharmaceutical agent.
SUMMARY OF THE INVENTION
This invention concerns an improvement in a process for converting a cyanoethylfluorene to an aminopropylfluorene. The invention more particularly provides, in the process for preparing a compound of the formula ##STR2## wherein R and R1 independently are hydrogen, C1 -C4 alkyl, fluoro or chloro; and R2 and R3 independently are hydrogen or C1 -C6 alkyl, involving catalytically hydrogenating a compound of the formula ##STR3## the improvement comprising conducting the reaction in the presence of an acid medium stronger than glacial acetic acid.
In a preferred embodiment of this invention the hydrogenation is carried out in the presence of trifluoroacetic acid. In another preferred embodiment the hydrogenation is carried out in the presence of a mineral acid such as hydrochloric acid.
DETAILED DESCRIPTION OF THE INVENTION
The process provided by this invention is carried out by catalytically hydrogenating a 9-carbamoyl-9-(2-cyanoethyl)fluorene in an acid medium stronger than glacial acetic acid. As pointed out in U.S. Pat. No. 4,282,170, the hydrogenation of the cyano group of a cyanoethylfluorene can be accomplished employing any of the common hydrogenation catalysts, including platinum, palladium, nickel, rhodium and ruthenium. The process generally will be carried out under a hydrogen pressure of about 1 to about 4 atmospheres, and typically at a temperature of about 20° to about 70° C.
The hydrogenation process of this invention can be carried out in essentially any organic solvent; all that is required is that about one molar equivalent or more of an acid stronger than glacial acetic acid be present in the reaction mixture. Organic solvents that can be employed include alcohols, ethers, aromatics, amides, as well as organic or inorganic acids and mixtures of acids. For example, the process is conveniently carried out in an alcohol such as methanol or ethanol together with at least about one molar quantity, relative to the cyanoethylfluorene to be reduced, of a strong acid such as 12N hydrochloric acid or the like.
Any acid that is stronger than acetic acid can be employed in the process of this invention. Such acids include those having a pKa less than about 4.75, the pKa of glacial acetic acid at 25° C. Exemplary of the strong acids that can be employed in the present process include benzosulfonic acid, any of the aminobenzosulfonic acids, ortho or meta-bromobenzoic acid, trichloroacetic acid, the chlorobenzoic acids, 2-chlorophenoxyacetic acid, 3-chlorophenoxyacetic acid, dimethylmalonic acid, dinicotonic acid, diphenylacetic acid, fluorobenzoic acid, formic acid, fluoroacetic acid, glycolic acid, hippuric acid, 2-hydroxybenzoic acid, 2-iodobenzoic acid, itacomic acid, lutidinic acid, maleic acid, malonic acid, mesaconic acid, methylmalonic acid, naphthalenesulfonic acid, α-naphthoic acid, oxalic acid, o-phthalic acid, quinolinic acid, sulfanilic acid, α-tartaric acid, trichloroacetic acid, trifluoroacetic acid, 2,4,6-trihydroxybenzoic acid, and similar strong organic acid. Inorganic acids can also be employed and exemplary of such acids are arsenic acid, chromic acid, hydrofluoric acid, hydrochloric acid, iodic acid, nitrous acid, periodic acid, phosphoric acid, pyrophosphoric acid, selenic acid, sulfuric acid, and related strong inorganic acids.
While the mechanism of the present process is not completely understood, it is believed that the strong acid required to be employed according to the invention reacts with the primary amino group of the 9-(3-aminopropyl)fluorene as it is formed to produce an acid addition salt. Once the primary amino group is protonated as an acid addition salt, it is unavailable for reaction with other reaction intermediates to produce the dimer and trimer by-products.
The hydrogenation process of this invention generally is substantially complete within about two to about twenty-four hours when carried out at about ambient temperature and under a hydrogen pressure of about 1 to about 4 atmospheres. The 9-carbamoyl-9-(3-aminopropyl)fluorene that is produced by the process is readily isolated by established procedures if desired. For example, the reaction mixture can be filtered to remove the hydrogenation catalyst, and the reaction solvent can be removed from the filtrate, for instance by evaporation under reduced pressure. The aminopropylfluorene product can be isolated and crystallized as an acid addition salt, or if desired the salt can be neutralized by reaction with a base such as sodium hydroxide or ammonium hydroxide to provide the desired primary amine.
In a preferred embodiment of the invention the 9-carbamoyl-9-(3-aminopropyl)fluorene is not isolated, but rather is reacted further in situ to produce an N-alkyl derivative such as 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene. Such alkylation is best accomplished by first neutralizing any excess acid, for instance by addition of a base such as sodium bicarbonate, and then simply adding an aldehyde or a ketone to the hydrogenation reaction mixture and subjecting the mixture to further hydrogenation. The aldehyde or ketone reacts with the primary amino group of the 9-carbamoyl-9-(3-aminopropyl)fluorene to produce the corresponding Schiff base, which upon further hydrogenation is reduced to the desired N-alkyl derivative. For example, 9-carbamoyl-9-(2-cyanoethyl)fluorene can be hydrogenated according to this invention by reaction with hydrogen gas in the presence of a catalyst such as platinum oxide and a strong acid such as trichloroacetic acid to produce, substantially free of dimer or trimer by-products, 9-carbamoyl-9-(3-aminopropyl)fluorene. The reaction mixture is neutralized by addition of a base, for example about one molar quantity or an excess of sodium hydroxide or the like. A ketone such as acetone can be added to the neutralized reaction mixture and the mixture can be further hydrogenated to provide 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene. The product thus produced is substantially free of undesired by-products and can be isolated and purified by routine procedures.
The process improvement provided by this invention is further illustrated by the following detailed examples. The examples are not intended to limit the invention in any respect and should not be so construed.
EXAMPLE 1
A mixture of 100 g of 9-carbamoyl-9-(2-cyanoethyl)fluorene and 20 g of 5% palladium on charcoal in 560 ml of tetrahydrofuran and 50 ml of water was stirred at 100° C. for twenty-four hours under 1000 psi of hydrogen. The reaction mixture was filtered and the filtrate was concentrated to dryness to provide 93.5 g of a white solid identified as primarily dimer and trimer product. The solid was suspended in 500 ml of acetone and the mixture was stirred at 25° C. for one hour and then filtered to give 34 g of a white solid. The filtrate was concentrated to give 50 g of a white solid. The white solids were combined and triturated in 675 ml of hot tetrahydrofuran. The mixture was filtered and the solvent was removed from the filtrate to give 69.9 g of a white solid melting at 162.5°-165° C. The solid was chromatographed twice over silica gel, eluting with tetrahydrofuran, to give a substantially pure sample of ##STR4##
Analysis calculated for C34 H33 N3 O2 : Theory: C, 79.19; H, 6.45; N, 8.15; Found: C, 77.17; H, 6.33; N, 7.39.
Eight grams of the above dimer were added to 200 ml of ethyl acetate and 150 ml of methanol containing 1.8 g of maleic acid. The reaction mixture was heated at 100° C. for one hour and then cooled. The crystalline precipitate was filtered and air dried to give 9.8 g of 9,9'-(iminodi-3,1-propanediyl)bis[9H-fluorene-9-carboxamide](Z)-2-butene-dioate (1:1) having the formula ##STR5##
M.P. 185°-187° C.
Analysis calculated for C38 H37 N3 O6 : Theory: C, 72.25; H, 5.90; N, 6.65; Found: C, 71.97; H, 6.00; N, 6.40.
EXAMPLE 2
A mixture of 15.02 g (57.2 mM) of 9-carbamoyl-9-(2-cyanoethyl)fluorene and 4.0 g platinum oxide in 200 ml of glacial acetic acid was shaken at 25° C. under a hydrogen atmosphere (4 atm) for three hours. The reaction mixture was diluted by addition of 5.0 g (86 mM) of acetone, and hydrogenation was continued for an additional seventeen hours. The reaction mixture was filtered and the filtrate was concentrated to dryness by evaporation of the solvents under reduced pressure to give 32.0 g of a brown viscous oil. The oil was added to 200 ml of ethyl acetate and 200 ml of ice water, and this mixture was diluted by addition of 400 ml of 6N hydrochloric acid. The aqueous acid layer was separated, made alkaline by addition of 110 ml of 50% aqueous sodium hydroxide. The aqueous alkaline solution was extracted several times with diethyl ether, and the ethereal extracts were combined, washed with water, dried and the solvent was removed by evaporation to give 13.4 g (76.1% yield) of product. The product was shown by high performance liquid chromatography to be comprised of 83.4% 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene and 8.2% of dimer, N,N-bis-[3-(9-carbamoylfluoren-9-yl)propyl]amine, identical to that prepared and characterized in Example 1.
EXAMPLE 3
A solution of 10.1 g (38 mM) of 9-carbamoyl-9-(2-cyanoethyl)fluorene in 190 ml of glacial acetic acid and 3.3 ml of 12N hydrochloric acid containing 2.0 g of platinum oxide was shaken for six hours at 25° C. in a Parr hydrogenator under 4 atm. of hydrogen. The reaction mixture was neutralized by addition of 3.1 g (38 mM) of sodium acetate, followed by addition of 8.34 ml of acetone. The reaction mixture was shaken for an additional sixteen hours under 4 atm. of hydrogen. An additional 2.75 ml of acetone were added to the reaction mixture and it was shaken under hydrogen for another two hours. The reaction mixture was filtered and the filtrate was concentrated to 36.0 g of a viscous liquid. The liquid was dissolved in 200 ml of water and the aqueous solution was washed with diethyl ether and then made alkaline by addition of 50% (w/v) aqueous sodium hydroxide. The alkaline mixture was extracted several times with diethyl ether and the ethereal extracts were combined, washed with water and dried. Removal of the solvent by evaporation under reduced pressure afforded 9.6 g (82% yield) of a tan solid.
A solution of 9.4 g of the tan solid in 110 ml of acetone was cooled to 0°-5° C. and diluted by addition of 3 ml of 12N hydrochloric acid. The reaction mixture was stirred at 0°-5° C. for one hour, whereupon the white precipitate that had formed was collected by filtration and air dried to give 7.6 g of a product melting at 191°-194° C.
The product thus obtained was crystallized from 90 ml of hot (80° C.) isopropanol to give 4.8 g of 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene hydrochloride melting at 205°-207° C. High performance liquid chromatography demonstrated the product to be at least 97.6% pure, with less than 1% of dimer being present.
Analysis calculated for C20 H25 ClN2 O: Theory: C, 69.65; H, 7.31; N, 8.12; Found: C, 69.84; H, 7.47; N, 7.92.
NMR (DMSOd6): δ 1.1 (d, 6H); 2.1-3.3 (m, 6H); 3.42 (s, 1H); 6.3 (s, 1H); 7.0 (s, 1H); 7.4-8.2 (m, 8H); 8.6-9.0 (broad s, 2H).
EXAMPLE 4
A solution of 10.1 g of 9-carbamoyl-9-(2-cyanoethyl)fluorene in 193 ml of glacial acetic acid and 8.66 g of trifluoroacetic acid containing 2.0 g of platinum oxide was shaken for six hours under 4 atm. of hydrogen in a Parr hydrogenation flask. The reaction mixture was filtered and the filtrate was concentrated to give 28.6 g of a viscous liquid. The liquid was added to 200 ml of ice water and the aqueous mixture was washed with dichloromethane. The aqueous layer was made alkaline by addition of 50% (w/v) aqueous sodium hydroxide, and the aqueous alkaline solution was extracted several times with dichloromethane. The organic extracts were combined, washed with water, dried, and the solvent was removed by evaporation under reduced pressure to give 9.9 g (97% yield) of a tan solid identified by thin layer chromatography as 9-carbamoyl-9-(3-aminopropyl)fluorene.
A solution of 9.1 g of the product from above in 190 ml of ethanol and 8.34 ml (6.66 g, 114 mM) of acetone containing 2.0 g of 5% palladium on charcoal was shaken for twenty hours at 25° C. under 4 atm of hydrogen. The reaction mixture was filtered and the filtrate was concentrated to 13.1 g of a viscous liquid. The liquid was added to 200 ml of water and 200 ml of diethyl ether. The aqueous layer was separated, made alkaline by addition of 50% sodium hydroxide, and extracted several times with diethyl ether. The ethereal extracts were combined, extracted with 300 ml of 6N hydrochloric acid and 200 ml of water. The aqueous acid extracts were combined, made alkaline, and then extracted with fresh diethyl ether. The ethereal extracts were combined, washed with water, dried and concentrated to give 9.9 g (84.6% yield) of a white solid. The solid was dissolved in 100 ml of cold (0°-5° C.) acetone and the solution was saturated with hydrogen chloride. The mixture was stirred for forty-five minutes and filtered to give 8.0 g (77.8%) of 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene hydrochloride. The product was recrystallized from isopropanol to give 4.7 g (58.7% yield) of the hydrochloride salt melting at 206°-208° C.
High pressure liquid chromatography established the product to be almost 100% 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene hydrochloride, with no detectible amounts of dimer or trimer.
Analysis calculated for C20 H25 ClN2 O: Theory: C, 69.65; H, 7.31; N, 8.12; Found: C, 69.90; H, 7.44; N, 8.03.
NMR (DMSOd6): δ 1.1 (d, 6H); 2.1-3.4 (m, 7H); 6.22 (s, 1H); 7.0 (s, 1H) 7.4-8.2 (m, 8H); 8.5-9.1 (broad s, 2H)
EXAMPLE 5
A solution of 10.1 g (38 mM) of 9-carbamoyl-9-(2-cyanoethyl)fluorene in 190 ml of ethanol and 8.66 g (76 mM) of trifluoroacetic acid containing 2.0 g of platinum oxide was shaken for four and one-half hours at 25° C. under 4 atm. of hydrogen. The reaction mixture was then added to a mixture of 2.0 g of 5% palladium on charcoal in 20 ml of ethanol containing 8.34 ml of acetone and 6.3 g sodium acetate. This reaction mixture was shaken for twenty hours at 25° C. under 4 atm. of hydrogen. The reaction mixture was filtered and the filtrate was concentrated to give 32.2 g of a viscous oil. The oil was added to 200 ml of ice water and the aqueous mixture was made alkaline by addition of 50% (w/v) aqueous sodium hydroxide. The aqueous alkaline mixture was extracted several times with diethyl ether. The ethereal extracts were combined and extracted with 300 ml of 6N hydrochloric acid and 200 ml of water. The aqueous acid extracts were combined, made alkaline by addition of fresh sodium hydroxide, and extracted with fresh diethyl ether. The ethereal extracts were combined, washed with water, dried and concentrated to dryness to give 11.1 g (94.8% yield) of product. The product was dissolved in 80 ml of acetone and the solution was saturated with hydrogen chloride to give 10.2 g (91.8%) of white solid. The solid was crystallized from 105 ml of isopropanol to provide 6.8 g (66.5%) of 9-carbamoyl-9-(3-isopropylaminopropyl)fluorene hydrochloride. M.P. 205°-208° C. High performance liquid chromatography demonstrated that the product contained no detectable amount of dimer or trimer. Elemental analysis and NMR were consistent with those for the products of Examples 3 and 4.

Claims (7)

We claim:
1. In a process for preparing a compound of the formula ##STR6## wherein: R and R1 independently are hydrogen, C1 -C4 alkyl, fluoro or chloro; and
R2 and R3 independently are hydrogen or C1 -C6 alkyl;
which includes catalytically hydrogenating a compound of the formula ##STR7## the improvement comprising conducting the reaction in the presence of an acid medium stronger than glacial acetic acid.
2. The process according to claim 1 employing trifluoroacetic acid.
3. The process according to claim 1 employing a mineral acid.
4. The process according to claim 1 wherein R and R1 both are hydrogen.
5. The process according to claim 4 wherein R2 and R3 both are hydrogen.
6. The process according to claim 5 employing trifluoroacetic acid.
7. The process according to claim 5 employing hydrochloric acid.
US06/519,166 1983-08-01 1983-08-01 Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes Expired - Fee Related US4552982A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US06/519,166 US4552982A (en) 1983-08-01 1983-08-01 Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes
US06/685,924 US4658061A (en) 1983-08-01 1984-12-24 9-aminoalkylfluorenes
DK332585A DK332585A (en) 1983-08-01 1985-07-22 METHOD FOR PREPARING 9-CARBAMOYL-9- (3-AMINOPROPYL) FLUORENES
AT0221185A AT383116B (en) 1983-08-01 1985-07-25 METHOD FOR THE PRODUCTION OF 9-CARBAMOYL-9- (3-AMINOPROPYL) FLUORENENE
HU852828A HU194537B (en) 1983-08-01 1985-07-25 Improved process for preparing 9-carbamoyl-9-/3-amino-propyl/-fluorene derivatives
CN198585106400A CN85106400A (en) 1983-08-01 1985-08-26 The synthetic method of 9-carbamyl-9-(3-aminopropyl) fluorenes that has improved
JP60289085A JPS61158944A (en) 1983-08-01 1985-12-20 9-aminoalkylfluorenes
EP85309313A EP0187509A3 (en) 1983-08-01 1985-12-20 9-aminoalkylfluorenes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US06/519,166 US4552982A (en) 1983-08-01 1983-08-01 Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes
US06/685,924 US4658061A (en) 1983-08-01 1984-12-24 9-aminoalkylfluorenes
DK332585A DK332585A (en) 1983-08-01 1985-07-22 METHOD FOR PREPARING 9-CARBAMOYL-9- (3-AMINOPROPYL) FLUORENES
AT0221185A AT383116B (en) 1983-08-01 1985-07-25 METHOD FOR THE PRODUCTION OF 9-CARBAMOYL-9- (3-AMINOPROPYL) FLUORENENE
HU852828A HU194537B (en) 1983-08-01 1985-07-25 Improved process for preparing 9-carbamoyl-9-/3-amino-propyl/-fluorene derivatives
CN198585106400A CN85106400A (en) 1983-08-01 1985-08-26 The synthetic method of 9-carbamyl-9-(3-aminopropyl) fluorenes that has improved

Publications (1)

Publication Number Publication Date
US4552982A true US4552982A (en) 1985-11-12

Family

ID=39577870

Family Applications (2)

Application Number Title Priority Date Filing Date
US06/519,166 Expired - Fee Related US4552982A (en) 1983-08-01 1983-08-01 Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes
US06/685,924 Expired - Fee Related US4658061A (en) 1983-08-01 1984-12-24 9-aminoalkylfluorenes

Family Applications After (1)

Application Number Title Priority Date Filing Date
US06/685,924 Expired - Fee Related US4658061A (en) 1983-08-01 1984-12-24 9-aminoalkylfluorenes

Country Status (7)

Country Link
US (2) US4552982A (en)
EP (1) EP0187509A3 (en)
JP (1) JPS61158944A (en)
CN (1) CN85106400A (en)
AT (1) AT383116B (en)
DK (1) DK332585A (en)
HU (1) HU194537B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658061A (en) * 1983-08-01 1987-04-14 Eli Lilly And Company 9-aminoalkylfluorenes
US5318935A (en) * 1990-12-27 1994-06-07 Exxon Chemical Patents Inc. Amido transition metal compound and a catalyst system for the production of isotatic polypropylene
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US20060196130A1 (en) * 2005-03-07 2006-09-07 Canplas Industries Ltd. Ridge vent apparatus

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823203D0 (en) * 1988-10-04 1988-11-09 Pfizer Ltd Therapeutic agents
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
US8128830B2 (en) 2009-09-17 2012-03-06 Hitachi Global Storage Technologies Netherlands, B.V. Labeling an imprint lithography template

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (en) * 1960-02-12 1962-03-01 Hoechst Ag Process for the preparation of analeptically active phenylcycloalkylmethylamines
GB1164354A (en) * 1966-07-04 1969-09-17 Toyo Rayon Co Ltd Process for the Hydrogenation of Nitriles.
US3468953A (en) * 1965-07-08 1969-09-23 Ugine Kuhlmann Process for manufacture of methylamines
US4197313A (en) * 1979-03-12 1980-04-08 Eli Lilly And Company Antiarrhythmic method
US4277471A (en) * 1979-03-12 1981-07-07 Eli Lilly And Company 1,1-Biphenyl-2-yl alkylamines, formulations and antiarrhythmic treatment
US4282170A (en) * 1980-04-17 1981-08-04 Eli Lilly And Company 9-Carbamoyl-9-(2-cyanoethyl)fluorenes
US4382093A (en) * 1980-04-17 1983-05-03 Eli Lilly And Company 9-Aminoalkylfluorenes
US4452745A (en) * 1981-02-06 1984-06-05 Eli Lilly And Company 9-Aminoalkylfluorenes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660485A (en) * 1970-10-05 1972-05-02 Searle & Co Fluorene-9-carboxylic acid hydrazides
US3843657A (en) * 1972-12-08 1974-10-22 Searle & Co 9-dialkylamin oalkyl-n-substituted fluorene-9-carboxamides
MA18763A1 (en) * 1979-03-12 1980-10-01 Lilly Co Eli PROCESS FOR THE PREPARATION OF 9-AMINOALKYLFLUORENES
US4552982A (en) * 1983-08-01 1985-11-12 Eli Lilly And Company Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes
US4486592A (en) * 1983-10-19 1984-12-04 Eli Lilly And Company 9-Carbamoylfluorene derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (en) * 1960-02-12 1962-03-01 Hoechst Ag Process for the preparation of analeptically active phenylcycloalkylmethylamines
US3468953A (en) * 1965-07-08 1969-09-23 Ugine Kuhlmann Process for manufacture of methylamines
GB1164354A (en) * 1966-07-04 1969-09-17 Toyo Rayon Co Ltd Process for the Hydrogenation of Nitriles.
US4197313A (en) * 1979-03-12 1980-04-08 Eli Lilly And Company Antiarrhythmic method
US4277471A (en) * 1979-03-12 1981-07-07 Eli Lilly And Company 1,1-Biphenyl-2-yl alkylamines, formulations and antiarrhythmic treatment
US4282170A (en) * 1980-04-17 1981-08-04 Eli Lilly And Company 9-Carbamoyl-9-(2-cyanoethyl)fluorenes
US4382093A (en) * 1980-04-17 1983-05-03 Eli Lilly And Company 9-Aminoalkylfluorenes
US4452745A (en) * 1981-02-06 1984-06-05 Eli Lilly And Company 9-Aminoalkylfluorenes

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658061A (en) * 1983-08-01 1987-04-14 Eli Lilly And Company 9-aminoalkylfluorenes
US5318935A (en) * 1990-12-27 1994-06-07 Exxon Chemical Patents Inc. Amido transition metal compound and a catalyst system for the production of isotatic polypropylene
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6472414B1 (en) 1996-12-17 2002-10-29 Bristol-Myers Squibb Company Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US20060196130A1 (en) * 2005-03-07 2006-09-07 Canplas Industries Ltd. Ridge vent apparatus

Also Published As

Publication number Publication date
JPS61158944A (en) 1986-07-18
HU194537B (en) 1988-02-29
EP0187509A3 (en) 1987-11-11
AT383116B (en) 1987-05-25
US4658061A (en) 1987-04-14
CN85106400A (en) 1987-03-18
HUT40998A (en) 1987-03-30
EP0187509A2 (en) 1986-07-16
DK332585D0 (en) 1985-07-22
ATA221185A (en) 1986-10-15
DK332585A (en) 1987-01-23

Similar Documents

Publication Publication Date Title
SU679140A3 (en) Method of producing carbonyl substituted 1-sulphonylbenzimidazoles
US4552982A (en) Synthesis of 9-carbamoyl-9-(3-aminopropyl)fluorenes
Senkus The Preparation of Some Hexahydropyrimidines from Nitroparaffins1
US3950405A (en) Trans-4-aminomethylcyclohexane-1-carboxylic acid
US3947405A (en) Process for making neohesperidine dihydrochalcone
US5744648A (en) Process for the manufacture of 1, 3-cyclohexanedione
US2784228A (en) Alkaline hydrogenation of oximinoketones
US4978793A (en) Novel process for the preparation of serinol
US4092314A (en) Preparation of 4,6-diamino-5-arylazopyrimidines and adenine compounds
CA1241018A (en) Synthesis of 9-carbamoyl 9-(3-aminopropyl)fluorenes
US4031108A (en) 2-Hydroxymethyl-3-benzyloxypyridine-6-epoxyethane
Mardle et al. Bronchodilators giving reduced cardiovascular effects. Relative biological activities of the four isomers of 1-(3, 4-dihydroxyphenyl)-2-isopropylaminobutanol
US3948919A (en) 2-Hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-t-butylaminoethyl)pyridine preparation and intermediate compounds
KR870002018B1 (en) Process for preparation of 9-carbamoyl-9-(3-aminopropyl)fluorenes
US3017427A (en) 4-amino-2-sulfamylbenzoic acid esters
US3058992A (en) Intermediates for the preparation of
CA1276148C (en) Process for the preparation of -n-¬(hypoxanthin-9-yl)-pentyloxycarbonyl|-arginine
US2980683A (en) Process for preparing beta-substitutedethyl piperazines
US2824872A (en) Morpholino phenyl carbamates and production thereof
US4585894A (en) Process for producing 9-carbamoyl fluorene derivatives
EP0598383B1 (en) Process for the preparation of 5,6-diacetoxyindole
US4474987A (en) Process for preparing N,N-disubstituted p-phenylenediamine derivatives
SU698528A3 (en) Method of preparing n-alkyl derivatives of 1-phenyl-2-amino-1,3-propandiol or their salts racemates or optically active antipodes
US6121492A (en) Method for preparing 2-trifluoro-methoxy-aniline
SU505351A3 (en) The method of obtaining 1- (m-acyloxyphenyl) 1-hydroxy-2-alkylaminoethanes

Legal Events

Date Code Title Description
AS Assignment

Owner name: ELI LILLY AND COMPANY, 307 EAST MCCARTY STREET, IN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:LACEFIELD, WILLIAM B.;PFEIFER, WILLIAM;REEL/FRAME:004446/0148

Effective date: 19830728

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19971112

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362